The year is 2030 and biotechnology is recognized as one of humankind’s greatest intellectual enterprises. Cancer is a manageable disease and world hunger has largely been alleviated. The life sciences industry has been an investment hub for private and public investors for more than a decade and public opinion on biotechnology is at an all-time high. But what provided the impetus for biotechnology’s golden age? This track will explore the major hurdles our industry faces today, provide useful proposals on what can be done to remove those obstacles and provide a vision of what the industry will look like in 20 years.
Session to include:
Beyond the Crystal Ball: Biotech Visionaries in the Media
Thursday June 13th from 11:45am-1:00pm
As a culture driven by the media, we gravitate toward catchy headlines everyday: “The Broken R&D Model”, “The Future of Cancer Vaccines”, etc. These are the types of headlines that inspire and instill fear in the minds of life science pros. Whether we like it or not, the media serves as a cornerstone in our industry and has historically been able to predict significant industry trends and even make or break companies. So, what happens when you take some of the leading thought leaders in the media and ask them to look 20 years into the future? These masters of the written word to dust off their crystal balls, break out their tarot cards and offer insight into how the industry will look in the year 2030. Will cancer be an afterthought? Will homogeneous therapies be extinct? Will stems cells reign?
Carin Canale-Theakston, President, Canale Communications
Bradley Fikes, Reporter – Biotechnology, UT San Diego
Mandy Jackson, West Coast Editor, Scrip Intelligence
Alex Lash, Editor, Elsevier Business Intelligence
Dan Munro, Contributor, Forbes
2030’s Most Successful Investors: How do they do it?
Thursday June 13th 4:15pm-5:30pm
In the Year 2030 the glory days of biotechnology are back. Many private and public life science investors had record-breaking returns and dreams of a FaceBook style IPO became a reality. Join this provocative panel of leading public and private life science investors as they fast forward to the year 2030. They will share how their investments achieved amazing returns, why the IPO market once again welcomes innovative companies developing novel compounds and why biotechnology is once more the investment darling with private, public and retail investors.
Carol Gallagher, CEO, Calistoga Pharmaceuticals
Patrick Heron, General Partner, Frazier Healthcare
Christopher Earl, President, Innotrove, LLC
Matthew D. Perry, Portfolio Manager, BVF Partners
Dennis Purcell, Senior Managing Partner, Aisling Capital
The Science of Happiness: How Employee Well-Being Drives Success
Friday June 14th 9:00am-10:00am
Imagine in the year 2030, everybody in the workplace is happy! The advantages of a happier workplace have been getting a lot of press lately, including the cover of the Harvard Business Review last year. Top academic research over the last 15 years has shown that happier employees are more engaged, creative, productive and resilient and they build stronger work relationships. The data shows, without a doubt, that happiness leads to success.
Eric Karpinski, The Happiness Coach, Happiness Advantage Master Trainer
Clinical Trials of the Future
Friday June 14th from 11:30am-12:45pm
Is it any surprise that drug development takes an average of 12 years and costs over a billion dollars? For the last 50 years, the way in which we conduct clinical trials has remained largely the same. We are using inefficient and outdated techniques and don’t take advantage of the newest technologies. But what does the clinical trial of the future look like? New tools and technologies are being implemented that will transform the way we conduct clinical trials, reducing the time and cost that it takes to get a drug to market. Industry visionaries that are developing the tools of the future will discuss new recruiting techniques, mobile health technologies for remote patient monitoring, innovative trial designs and industry-wide consortiums that will ultimately revolutionize the way we conduct clinical trials, reducing costs and speeding drug development. The panel will be conducted in a futuristic storytelling fashion, looking at the entire clinical trial process with real technologies currently being tested as if they were all being implemented as standard practice across the industry.
Ronan Brown, VP & Managing Director, Customer Solutions Management Group, Quintiles
Ronald M.B.S. Demuth, President, Torrey Pines Investment
Andreas Koester, M.D., Ph.D., VP Clinical Trial Innovation / External Alliances, Janssen, Pharmaceutical Companies of Johnson & Johnson